Key clinical point: Patients with chronic-phase chronic myeloid leukemia (CML-CP) who achieved an early (within 24 months) complete cytogenetic response (CCyR) to tyrosine kinase inhibitor (TKI) therapy (responders) had more favorable outcomes. However, continued TKI therapy led to late responses in a proportion of patients initially refractory to TKIs (nonresponders).

Major finding: During a median follow-up of 8.1 years, responders vs non-responders had significantly higher overall survival (93% vs 85%) and progression-free survival (93% vs 75%; both P less than .001) and lower progression to blast phase (1.9% vs 10.4%; P = .004). However, 34% of early nonresponders achieved CCyR with continued TKI therapy.

Study details: Findings are from a retrospective analysis of 305 adult patients with CML-CP treated with TKIs between 2001 and 2014.

Disclosures: This work was supported by the Thomas H. Brown Research Fund for Blood Cancers. M Talpaz reported ties with Novartis US and Takeda. Other authors declared no conflict of interests.

Source: Shaya J et al. Clin Lymphoma Myeloma Leuk. 2021 Jul 18. doi: 10.1016/j.clml.2021.07.001.

Key clinical point: Patients with chronic-phase chronic myeloid leukemia (CML-CP) who achieved an early (within 24 months) complete cytogenetic response (CCyR) to tyrosine kinase inhibitor (TKI) therapy (responders) had more favorable outcomes. However, continued TKI therapy led to late responses in a proportion of patients initially refractory to TKIs (nonresponders).

Major finding: During a median follow-up of 8.1 years, responders vs non-responders had significantly higher overall survival (93% vs 85%) and progression-free survival (93% vs 75%; both P less than .001) and lower progression to blast phase (1.9% vs 10.4%; P = .004). However, 34% of early nonresponders achieved CCyR with continued TKI therapy.

Study details: Findings are from a retrospective analysis of 305 adult patients with CML-CP treated with TKIs between 2001 and 2014.

Disclosures: This work was supported by the Thomas H. Brown Research Fund for Blood Cancers. M Talpaz reported ties with Novartis US and Takeda. Other authors declared no conflict of interests.

Source: Shaya J et al. Clin Lymphoma Myeloma Leuk. 2021 Jul 18. doi: 10.1016/j.clml.2021.07.001.

Key clinical point: Patients with chronic-phase chronic myeloid leukemia (CML-CP) who achieved an early (within 24 months) complete cytogenetic response (CCyR) to tyrosine kinase inhibitor (TKI) therapy (responders) had more favorable outcomes. However, continued TKI therapy led to late responses in a proportion of patients initially refractory to TKIs (nonresponders).

Major finding: During a median follow-up of 8.1 years, responders vs non-responders had significantly higher overall survival (93% vs 85%) and progression-free survival (93% vs 75%; both P less than .001) and lower progression to blast phase (1.9% vs 10.4%; P = .004). However, 34% of early nonresponders achieved CCyR with continued TKI therapy.

Study details: Findings are from a retrospective analysis of 305 adult patients with CML-CP treated with TKIs between 2001 and 2014.

Disclosures: This work was supported by the Thomas H. Brown Research Fund for Blood Cancers. M Talpaz reported ties with Novartis US and Takeda. Other authors declared no conflict of interests.

Source: Shaya J et al. Clin Lymphoma Myeloma Leuk. 2021 Jul 18. doi: 10.1016/j.clml.2021.07.001.

Key clinical point: Among patients with chronic myeloid leukemia (CML) presenting with COVID-19, better prognosis was observed in patients with controlled disease and those on tyrosine kinase inhibitor (TKI) therapies.

Major finding: Patients with vs without major molecular response had superior overall survival (91% vs 61%; P = .0004). Moreover, patients in treatment-free remission (100%) or on TKI therapy (89%) had higher survival vs patients who underwent hematopoietic stem cell transplantation (50%) or not receiving TKI treatment (33%; P < .001).

Study details: Findings are from an observational study assessing COVID-19 outcomes in 92 patients with CML in Latin America between March and December 2020.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Pagnano KB et al. Leuk Lymphoma. 2021 Jul 13. doi: 10.1080/10428194.2021.1950709.

Key clinical point: Among patients with chronic myeloid leukemia (CML) presenting with COVID-19, better prognosis was observed in patients with controlled disease and those on tyrosine kinase inhibitor (TKI) therapies.

Major finding: Patients with vs without major molecular response had superior overall survival (91% vs 61%; P = .0004). Moreover, patients in treatment-free remission (100%) or on TKI therapy (89%) had higher survival vs patients who underwent hematopoietic stem cell transplantation (50%) or not receiving TKI treatment (33%; P < .001).

Study details: Findings are from an observational study assessing COVID-19 outcomes in 92 patients with CML in Latin America between March and December 2020.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Pagnano KB et al. Leuk Lymphoma. 2021 Jul 13. doi: 10.1080/10428194.2021.1950709.

Key clinical point: Among patients with chronic myeloid leukemia (CML) presenting with COVID-19, better prognosis was observed in patients with controlled disease and those on tyrosine kinase inhibitor (TKI) therapies.

Major finding: Patients with vs without major molecular response had superior overall survival (91% vs 61%; P = .0004). Moreover, patients in treatment-free remission (100%) or on TKI therapy (89%) had higher survival vs patients who underwent hematopoietic stem cell transplantation (50%) or not receiving TKI treatment (33%; P < .001).

Study details: Findings are from an observational study assessing COVID-19 outcomes in 92 patients with CML in Latin America between March and December 2020.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Pagnano KB et al. Leuk Lymphoma. 2021 Jul 13. doi: 10.1080/10428194.2021.1950709.

Key clinical point: Long-term analysis indicated clear growth deceleration over time during nilotinib treatment in pediatric patients with newly diagnosed or imatinib/dasatinib resistant/intolerant Philadelphia chromosome-positive (Ph⁺) chronic myeloid leukemia (CML).

Major finding: Overall median change in height standard deviation scores after 48 cycles of nilotinib treatment vs baseline was −0.54 (range, −1.6 to 0.4) in patients resistant/intolerant to imatinib or dasatinib and −0.91 (range, −1.4 to −0.1) in patients with newly diagnosed CML. No new safety concerns were reported.

Study details: Findings are from the phase 2 DIALOG study including 58 pediatric patients with newly diagnosed (n=25) or imatinib or dasatinib resistant/intolerant (n=33) Ph⁺ CML who received at least 48 cycles of nilotinib treatment or discontinued the study.

Disclosures: This study was sponsored and funded by Novartis Pharmaceuticals Corporation. Some investigators including the lead author reported ties with Novartis.

Source: Hijiya N et al. Blood Adv. 2021 Jul 26. doi: 10.1182/bloodadvances.2020003759.

Key clinical point: Long-term analysis indicated clear growth deceleration over time during nilotinib treatment in pediatric patients with newly diagnosed or imatinib/dasatinib resistant/intolerant Philadelphia chromosome-positive (Ph⁺) chronic myeloid leukemia (CML).

Major finding: Overall median change in height standard deviation scores after 48 cycles of nilotinib treatment vs baseline was −0.54 (range, −1.6 to 0.4) in patients resistant/intolerant to imatinib or dasatinib and −0.91 (range, −1.4 to −0.1) in patients with newly diagnosed CML. No new safety concerns were reported.

Study details: Findings are from the phase 2 DIALOG study including 58 pediatric patients with newly diagnosed (n=25) or imatinib or dasatinib resistant/intolerant (n=33) Ph⁺ CML who received at least 48 cycles of nilotinib treatment or discontinued the study.

Disclosures: This study was sponsored and funded by Novartis Pharmaceuticals Corporation. Some investigators including the lead author reported ties with Novartis.

Source: Hijiya N et al. Blood Adv. 2021 Jul 26. doi: 10.1182/bloodadvances.2020003759.

Key clinical point: Long-term analysis indicated clear growth deceleration over time during nilotinib treatment in pediatric patients with newly diagnosed or imatinib/dasatinib resistant/intolerant Philadelphia chromosome-positive (Ph⁺) chronic myeloid leukemia (CML).

Major finding: Overall median change in height standard deviation scores after 48 cycles of nilotinib treatment vs baseline was −0.54 (range, −1.6 to 0.4) in patients resistant/intolerant to imatinib or dasatinib and −0.91 (range, −1.4 to −0.1) in patients with newly diagnosed CML. No new safety concerns were reported.

Study details: Findings are from the phase 2 DIALOG study including 58 pediatric patients with newly diagnosed (n=25) or imatinib or dasatinib resistant/intolerant (n=33) Ph⁺ CML who received at least 48 cycles of nilotinib treatment or discontinued the study.

Disclosures: This study was sponsored and funded by Novartis Pharmaceuticals Corporation. Some investigators including the lead author reported ties with Novartis.

Source: Hijiya N et al. Blood Adv. 2021 Jul 26. doi: 10.1182/bloodadvances.2020003759.

Key clinical point: Higher incidence of uncontrolled blood pressure (BP) was observed in patients with chronic myeloid leukemia (CML) receiving nilotinib vs imatinib or dasatinib, which may be involved in the pro-atherogenic mechanism underlying the development of cardiovascular disease in nilotinib-treated patients.

Major finding: Overall, 47.9% of patients were hypertensive and 32.9% of patients showed uncontrolled BP (at least 130/80 mmHg) on 24-hour ambulatory BP monitoring (ABPM). Patients receiving nilotinib vs dasatinib or imatinib showed a higher incidence of uncontrolled BP in ABPM (45.5% vs 20%; P = .041).

Study details: This observational study assessed clinical BP and 24-hour ambulatory BP in 73 patients with CML receiving active tyrosine kinase inhibitor treatment with either imatinib, nilotinib, or dasatinib.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Roa-Chamorro R et al. Sci Rep. 2021 Jul 19. doi: 10.1038/s41598-021-94127-2.

Key clinical point: Higher incidence of uncontrolled blood pressure (BP) was observed in patients with chronic myeloid leukemia (CML) receiving nilotinib vs imatinib or dasatinib, which may be involved in the pro-atherogenic mechanism underlying the development of cardiovascular disease in nilotinib-treated patients.

Major finding: Overall, 47.9% of patients were hypertensive and 32.9% of patients showed uncontrolled BP (at least 130/80 mmHg) on 24-hour ambulatory BP monitoring (ABPM). Patients receiving nilotinib vs dasatinib or imatinib showed a higher incidence of uncontrolled BP in ABPM (45.5% vs 20%; P = .041).

Study details: This observational study assessed clinical BP and 24-hour ambulatory BP in 73 patients with CML receiving active tyrosine kinase inhibitor treatment with either imatinib, nilotinib, or dasatinib.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Roa-Chamorro R et al. Sci Rep. 2021 Jul 19. doi: 10.1038/s41598-021-94127-2.

Key clinical point: Higher incidence of uncontrolled blood pressure (BP) was observed in patients with chronic myeloid leukemia (CML) receiving nilotinib vs imatinib or dasatinib, which may be involved in the pro-atherogenic mechanism underlying the development of cardiovascular disease in nilotinib-treated patients.

Major finding: Overall, 47.9% of patients were hypertensive and 32.9% of patients showed uncontrolled BP (at least 130/80 mmHg) on 24-hour ambulatory BP monitoring (ABPM). Patients receiving nilotinib vs dasatinib or imatinib showed a higher incidence of uncontrolled BP in ABPM (45.5% vs 20%; P = .041).

Study details: This observational study assessed clinical BP and 24-hour ambulatory BP in 73 patients with CML receiving active tyrosine kinase inhibitor treatment with either imatinib, nilotinib, or dasatinib.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Roa-Chamorro R et al. Sci Rep. 2021 Jul 19. doi: 10.1038/s41598-021-94127-2.

Key clinical point: Treatment with new-generation tyrosine kinase inhibitors (TKIs), i.e., bosutinib, nilotinib, and ponatinib, but not dasatinib, increased the risk of hepatotoxicity compared with imatinib among patients with chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Overall, patients receiving new-generation TKIs vs imatinib were at an increased risk of all-grade alanine aminotransferase (ALT) elevation (relative risk [RR], 2.89), high-grade ALT elevation (RR, 4.36), all-grade aspartate aminotransferase (AST) elevation (RR, 2.20), and high-grade AST elevation (RR, 2.65; all P < .001). Dasatinib was not associated with an increased risk of ALT or AST elevation.

Study details: Findings are from a systematic review and meta-analysis of 9 studies, including 3,475 patients with CML-CP that compared hepatotoxicity of bosutinib, dasatinib, nilotinib, and ponatinib vs imatinib.

Disclosures: This work was funded by the National Key Research and Development Program of China and the Fundamental Research Funds for the Central Universities. The authors did not report any conflict of interests.

Source: Wang Z et al. JAMA Netw Open. 2021 Jul 22. doi: 10.1001/jamanetworkopen.2021.20165.

Key clinical point: Treatment with new-generation tyrosine kinase inhibitors (TKIs), i.e., bosutinib, nilotinib, and ponatinib, but not dasatinib, increased the risk of hepatotoxicity compared with imatinib among patients with chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Overall, patients receiving new-generation TKIs vs imatinib were at an increased risk of all-grade alanine aminotransferase (ALT) elevation (relative risk [RR], 2.89), high-grade ALT elevation (RR, 4.36), all-grade aspartate aminotransferase (AST) elevation (RR, 2.20), and high-grade AST elevation (RR, 2.65; all P < .001). Dasatinib was not associated with an increased risk of ALT or AST elevation.

Study details: Findings are from a systematic review and meta-analysis of 9 studies, including 3,475 patients with CML-CP that compared hepatotoxicity of bosutinib, dasatinib, nilotinib, and ponatinib vs imatinib.

Disclosures: This work was funded by the National Key Research and Development Program of China and the Fundamental Research Funds for the Central Universities. The authors did not report any conflict of interests.

Source: Wang Z et al. JAMA Netw Open. 2021 Jul 22. doi: 10.1001/jamanetworkopen.2021.20165.

Key clinical point: Treatment with new-generation tyrosine kinase inhibitors (TKIs), i.e., bosutinib, nilotinib, and ponatinib, but not dasatinib, increased the risk of hepatotoxicity compared with imatinib among patients with chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Overall, patients receiving new-generation TKIs vs imatinib were at an increased risk of all-grade alanine aminotransferase (ALT) elevation (relative risk [RR], 2.89), high-grade ALT elevation (RR, 4.36), all-grade aspartate aminotransferase (AST) elevation (RR, 2.20), and high-grade AST elevation (RR, 2.65; all P < .001). Dasatinib was not associated with an increased risk of ALT or AST elevation.

Study details: Findings are from a systematic review and meta-analysis of 9 studies, including 3,475 patients with CML-CP that compared hepatotoxicity of bosutinib, dasatinib, nilotinib, and ponatinib vs imatinib.

Disclosures: This work was funded by the National Key Research and Development Program of China and the Fundamental Research Funds for the Central Universities. The authors did not report any conflict of interests.

Source: Wang Z et al. JAMA Netw Open. 2021 Jul 22. doi: 10.1001/jamanetworkopen.2021.20165.

Key clinical point: Presence of SRSF2 mutations in patients with acute myeloid leukemia (AML) did not affect clinical outcomes after allogeneic hematopoietic stem cell transplantation (HSCT).

Major finding: Overall, 12.5% of patients harbored an SRSF2 mutation that persisted in 93% of analyzed patients in remission prior to HSCT. SRSF2 P95 mutation at diagnosis and HSCT did not affect the cumulative incidence of relapse (both P = .68), event-free survival (P = .40 and P = .80, respectively), or overall survival (P = .10 and P = .90, respectively) in patients with AML consolidated with HSCT in complete remission (CR) or CR with incomplete peripheral recovery.

Study details: Findings are from a retrospective analysis of 263 adult patients with AML who underwent allogeneic HSCT between May 2000 and August 2020.

Disclosures: This work was supported by the Deutsche José-Carreras-Stiftung, Deutsche Gesellschaft für Innere Medizin, Verein zusammen gegen den Krebs e.V., and Ein Herz für Kinder e.V. The authors declared no conflict of interests.

Source: Grimm J et al. Am J Hematol. 2021 Jul 21. doi: 10.1002/ajh.26298.

Key clinical point: Presence of SRSF2 mutations in patients with acute myeloid leukemia (AML) did not affect clinical outcomes after allogeneic hematopoietic stem cell transplantation (HSCT).

Major finding: Overall, 12.5% of patients harbored an SRSF2 mutation that persisted in 93% of analyzed patients in remission prior to HSCT. SRSF2 P95 mutation at diagnosis and HSCT did not affect the cumulative incidence of relapse (both P = .68), event-free survival (P = .40 and P = .80, respectively), or overall survival (P = .10 and P = .90, respectively) in patients with AML consolidated with HSCT in complete remission (CR) or CR with incomplete peripheral recovery.

Study details: Findings are from a retrospective analysis of 263 adult patients with AML who underwent allogeneic HSCT between May 2000 and August 2020.

Disclosures: This work was supported by the Deutsche José-Carreras-Stiftung, Deutsche Gesellschaft für Innere Medizin, Verein zusammen gegen den Krebs e.V., and Ein Herz für Kinder e.V. The authors declared no conflict of interests.

Source: Grimm J et al. Am J Hematol. 2021 Jul 21. doi: 10.1002/ajh.26298.

Key clinical point: Presence of SRSF2 mutations in patients with acute myeloid leukemia (AML) did not affect clinical outcomes after allogeneic hematopoietic stem cell transplantation (HSCT).

Major finding: Overall, 12.5% of patients harbored an SRSF2 mutation that persisted in 93% of analyzed patients in remission prior to HSCT. SRSF2 P95 mutation at diagnosis and HSCT did not affect the cumulative incidence of relapse (both P = .68), event-free survival (P = .40 and P = .80, respectively), or overall survival (P = .10 and P = .90, respectively) in patients with AML consolidated with HSCT in complete remission (CR) or CR with incomplete peripheral recovery.

Study details: Findings are from a retrospective analysis of 263 adult patients with AML who underwent allogeneic HSCT between May 2000 and August 2020.

Disclosures: This work was supported by the Deutsche José-Carreras-Stiftung, Deutsche Gesellschaft für Innere Medizin, Verein zusammen gegen den Krebs e.V., and Ein Herz für Kinder e.V. The authors declared no conflict of interests.

Source: Grimm J et al. Am J Hematol. 2021 Jul 21. doi: 10.1002/ajh.26298.

Key clinical point: New tumor protein 53 (TP53) mutations could be acquired during acute myeloid leukemia (AML) treatment, particularly after intensive chemotherapy and hematopoietic stem cell transplantation (HSCT), in a proportion of patients with TP53 wild-type AML. Thus, sequential monitoring for emergent TP53 mutations during AML therapy may have clinical relevance.

Major finding: Overall, 15% of patients developed a newly detectable TP53 mutation during AML therapy, with a median variant allele frequency of 15%. Newly detected TP53 mutations were frequent in patients receiving intensive vs low-intensity chemotherapy (23% vs 10%; P = .02) and those who underwent HSCT vs those who did not (36% vs 12%; P = .005).

Study details: Findings are from a retrospective analysis of 200 adult patients with newly diagnosed TP53 wild-type AML who relapsed after or were refractory to frontline therapy.

Disclosures: This study was supported by MD Anderson Cancer Center Support Grant and SPORE. The authors declared no conflict of interests.

Source: Alwash Y et al. Am J Hematol. 2021 Aug 5. doi: 10.1002/ajh.26314.

Key clinical point: New tumor protein 53 (TP53) mutations could be acquired during acute myeloid leukemia (AML) treatment, particularly after intensive chemotherapy and hematopoietic stem cell transplantation (HSCT), in a proportion of patients with TP53 wild-type AML. Thus, sequential monitoring for emergent TP53 mutations during AML therapy may have clinical relevance.

Major finding: Overall, 15% of patients developed a newly detectable TP53 mutation during AML therapy, with a median variant allele frequency of 15%. Newly detected TP53 mutations were frequent in patients receiving intensive vs low-intensity chemotherapy (23% vs 10%; P = .02) and those who underwent HSCT vs those who did not (36% vs 12%; P = .005).

Study details: Findings are from a retrospective analysis of 200 adult patients with newly diagnosed TP53 wild-type AML who relapsed after or were refractory to frontline therapy.

Disclosures: This study was supported by MD Anderson Cancer Center Support Grant and SPORE. The authors declared no conflict of interests.

Source: Alwash Y et al. Am J Hematol. 2021 Aug 5. doi: 10.1002/ajh.26314.

Key clinical point: New tumor protein 53 (TP53) mutations could be acquired during acute myeloid leukemia (AML) treatment, particularly after intensive chemotherapy and hematopoietic stem cell transplantation (HSCT), in a proportion of patients with TP53 wild-type AML. Thus, sequential monitoring for emergent TP53 mutations during AML therapy may have clinical relevance.

Major finding: Overall, 15% of patients developed a newly detectable TP53 mutation during AML therapy, with a median variant allele frequency of 15%. Newly detected TP53 mutations were frequent in patients receiving intensive vs low-intensity chemotherapy (23% vs 10%; P = .02) and those who underwent HSCT vs those who did not (36% vs 12%; P = .005).

Study details: Findings are from a retrospective analysis of 200 adult patients with newly diagnosed TP53 wild-type AML who relapsed after or were refractory to frontline therapy.

Disclosures: This study was supported by MD Anderson Cancer Center Support Grant and SPORE. The authors declared no conflict of interests.

Source: Alwash Y et al. Am J Hematol. 2021 Aug 5. doi: 10.1002/ajh.26314.

Key clinical point: Among patients with core binding factor (CBF)-acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT) in complete remission (CR), pretransplant measurable residual disease (MRD) predicts posttransplant outcomes differently in patients with t(8;21) and those with inv(16).

Major finding: Pretransplant MRD negativity was associated with lower relapse (hazard ratio [HR], 0.46; P less than .001), overall mortality (HR, 0.72; P = .037), and treatment failure (HR, 0.66; P = .004) among patients with t(8;21) AML but not those with inv(16) AML (all P > .05).

Study details: Findings are from a retrospective analysis of 959 patients with CBF-AML with either t(8;21) AML (n=631) or inv(16) AML (n=328) who underwent first allo-HCT in CR between 2000 and 2018.

Disclosures: This work was supported partly by the Practical Research Project for Allergic Diseases and Immunology from the Japan Agency for Medical Research and Development. The authors declared no conflict of interests.

Source: Konuma T et al. Bone Marrow Transplant. 2021 Jul 16. doi: 10.1038/s41409-021-01409-4.

Key clinical point: Among patients with core binding factor (CBF)-acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT) in complete remission (CR), pretransplant measurable residual disease (MRD) predicts posttransplant outcomes differently in patients with t(8;21) and those with inv(16).

Major finding: Pretransplant MRD negativity was associated with lower relapse (hazard ratio [HR], 0.46; P less than .001), overall mortality (HR, 0.72; P = .037), and treatment failure (HR, 0.66; P = .004) among patients with t(8;21) AML but not those with inv(16) AML (all P > .05).

Study details: Findings are from a retrospective analysis of 959 patients with CBF-AML with either t(8;21) AML (n=631) or inv(16) AML (n=328) who underwent first allo-HCT in CR between 2000 and 2018.

Disclosures: This work was supported partly by the Practical Research Project for Allergic Diseases and Immunology from the Japan Agency for Medical Research and Development. The authors declared no conflict of interests.

Source: Konuma T et al. Bone Marrow Transplant. 2021 Jul 16. doi: 10.1038/s41409-021-01409-4.

Key clinical point: Among patients with core binding factor (CBF)-acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT) in complete remission (CR), pretransplant measurable residual disease (MRD) predicts posttransplant outcomes differently in patients with t(8;21) and those with inv(16).

Major finding: Pretransplant MRD negativity was associated with lower relapse (hazard ratio [HR], 0.46; P less than .001), overall mortality (HR, 0.72; P = .037), and treatment failure (HR, 0.66; P = .004) among patients with t(8;21) AML but not those with inv(16) AML (all P > .05).

Study details: Findings are from a retrospective analysis of 959 patients with CBF-AML with either t(8;21) AML (n=631) or inv(16) AML (n=328) who underwent first allo-HCT in CR between 2000 and 2018.

Disclosures: This work was supported partly by the Practical Research Project for Allergic Diseases and Immunology from the Japan Agency for Medical Research and Development. The authors declared no conflict of interests.

Source: Konuma T et al. Bone Marrow Transplant. 2021 Jul 16. doi: 10.1038/s41409-021-01409-4.

Key clinical point: Fluid overload (FO) associated with increased administration of crystalloid fluids affected survival in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. Weight-adjusted prescription of crystalloid fluids may reduce the risk for FO in this patient population.

Major finding: FO was observed in 12.3% of patients with AML. Patients receiving more than 100 mL crystalloid fluids/kg body weight were at a higher risk for FO (odds ratio, 2.78; P = .033). Patients with FO had inferior 90-day survival vs those without FO (P = .0044).

Study details: Findings are from a retrospective analysis of 187 adult patients with AML receiving induction chemotherapy between 2014 and 2019.

Disclosures: Open Access funding was enabled and organized by Projekt DEAL. The authors declared no conflict of interests.

Source: Ballo O et al. Ann Hematol. 2021 Jul 25. doi: 10.1007/s00277-021-04593-x.

Key clinical point: Fluid overload (FO) associated with increased administration of crystalloid fluids affected survival in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. Weight-adjusted prescription of crystalloid fluids may reduce the risk for FO in this patient population.

Major finding: FO was observed in 12.3% of patients with AML. Patients receiving more than 100 mL crystalloid fluids/kg body weight were at a higher risk for FO (odds ratio, 2.78; P = .033). Patients with FO had inferior 90-day survival vs those without FO (P = .0044).

Study details: Findings are from a retrospective analysis of 187 adult patients with AML receiving induction chemotherapy between 2014 and 2019.

Disclosures: Open Access funding was enabled and organized by Projekt DEAL. The authors declared no conflict of interests.

Source: Ballo O et al. Ann Hematol. 2021 Jul 25. doi: 10.1007/s00277-021-04593-x.

Key clinical point: Fluid overload (FO) associated with increased administration of crystalloid fluids affected survival in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. Weight-adjusted prescription of crystalloid fluids may reduce the risk for FO in this patient population.

Major finding: FO was observed in 12.3% of patients with AML. Patients receiving more than 100 mL crystalloid fluids/kg body weight were at a higher risk for FO (odds ratio, 2.78; P = .033). Patients with FO had inferior 90-day survival vs those without FO (P = .0044).

Study details: Findings are from a retrospective analysis of 187 adult patients with AML receiving induction chemotherapy between 2014 and 2019.

Disclosures: Open Access funding was enabled and organized by Projekt DEAL. The authors declared no conflict of interests.

Source: Ballo O et al. Ann Hematol. 2021 Jul 25. doi: 10.1007/s00277-021-04593-x.

Key clinical point: Among patients with relapsed acute myeloid leukemia (AML) following allogeneic stem cell transplant (allo-SCT), high-intensity chemotherapy followed by cell therapy (CT), such as second allo-SCT or donor lymphocyte infusion (DLI), led to improved survival vs other treatment options.

Major finding: Overall survival at 1 year was significantly higher in patients receiving high-intensity chemotherapy prior to CT (52.9%) vs high-intensity chemotherapy alone (10%), low-intensity chemotherapy alone (5%), and low-intensity chemotherapy followed by CT (23.1%; P <  .001).

Study details: Findings are from a retrospective analysis of 69 patients with AML who relapsed following allo-SCT between January 2014 and August 2019 (n=172). Relapsed patients received either second allo-SCT (n=4), DLI (n=26), chemotherapy alone (n=31), or no treatment (n=8).

Disclosures: No specific source of funding was identified. The authors declared no conflict of interests.

Source: Shah N et al. Ann Hematol. 2021 Jul 29. doi: 10.1007/s00277-021-04616-7.

Key clinical point: Among patients with relapsed acute myeloid leukemia (AML) following allogeneic stem cell transplant (allo-SCT), high-intensity chemotherapy followed by cell therapy (CT), such as second allo-SCT or donor lymphocyte infusion (DLI), led to improved survival vs other treatment options.

Major finding: Overall survival at 1 year was significantly higher in patients receiving high-intensity chemotherapy prior to CT (52.9%) vs high-intensity chemotherapy alone (10%), low-intensity chemotherapy alone (5%), and low-intensity chemotherapy followed by CT (23.1%; P <  .001).

Study details: Findings are from a retrospective analysis of 69 patients with AML who relapsed following allo-SCT between January 2014 and August 2019 (n=172). Relapsed patients received either second allo-SCT (n=4), DLI (n=26), chemotherapy alone (n=31), or no treatment (n=8).

Disclosures: No specific source of funding was identified. The authors declared no conflict of interests.

Source: Shah N et al. Ann Hematol. 2021 Jul 29. doi: 10.1007/s00277-021-04616-7.

Key clinical point: Among patients with relapsed acute myeloid leukemia (AML) following allogeneic stem cell transplant (allo-SCT), high-intensity chemotherapy followed by cell therapy (CT), such as second allo-SCT or donor lymphocyte infusion (DLI), led to improved survival vs other treatment options.

Major finding: Overall survival at 1 year was significantly higher in patients receiving high-intensity chemotherapy prior to CT (52.9%) vs high-intensity chemotherapy alone (10%), low-intensity chemotherapy alone (5%), and low-intensity chemotherapy followed by CT (23.1%; P <  .001).

Study details: Findings are from a retrospective analysis of 69 patients with AML who relapsed following allo-SCT between January 2014 and August 2019 (n=172). Relapsed patients received either second allo-SCT (n=4), DLI (n=26), chemotherapy alone (n=31), or no treatment (n=8).

Disclosures: No specific source of funding was identified. The authors declared no conflict of interests.

Source: Shah N et al. Ann Hematol. 2021 Jul 29. doi: 10.1007/s00277-021-04616-7.